Utility of chromosomal microarray for diagnosis in cases of nonimmune hydrops fetalis.


Journal

Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540

Informations de publication

Date de publication:
03 2020
Historique:
received: 29 05 2019
revised: 26 08 2019
accepted: 11 10 2019
pubmed: 26 1 2020
medline: 25 3 2021
entrez: 26 1 2020
Statut: ppublish

Résumé

Chromosomal microarray (CMA) is recommended in the diagnostic evaluation of cases with fetal structural anomalies when invasive testing is pursued. However, the utility of CMA for nonimmune hydrops fetalis (NIHF) specifically is not well known. Our objective was to describe the overall yield of CMA in the diagnostic evaluation of NIHF, comparing isolated cases to those with concurrent structural anomalies. This was a retrospective cohort study of all prenatally diagnosed NIHF cases evaluated at the University of California, San Francisco from 2008 to 2018. NIHF due to twin-twin transfusion syndrome was excluded. There were 131 cases of prenatally diagnosed NIHF. In 43/44 cases with a CMA performed, results were categorized as normal or likely benign. One case was found on CMA to have a large pathogenic duplication of 21p11.2q22.3, which could have been detected by karyotype and was consistent with a diagnosis of Down syndrome. There was no incremental yield demonstrated for CMA over karyotype. Among a cohort of prenatally diagnosed NIHF cases, CMA did not identify any copy number variants beyond those detectable by karyotype, and the vast majority of CMAs were normal. These results suggest that CMA has low diagnostic utility for NIHF.

Identifiants

pubmed: 31981373
doi: 10.1002/pd.5617
pmc: PMC7153803
mid: NIHMS1565597
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

492-496

Subventions

Organisme : NICHD NIH HHS
ID : K12 HD001262
Pays : United States

Informations de copyright

© 2020 John Wiley & Sons, Ltd.

Références

Am J Obstet Gynecol. 2015 Feb;212(2):127-39
pubmed: 25557883
Obstet Gynecol. 2016 Dec;128(6):e262-e268
pubmed: 27875474
Prenat Diagn. 2015 Jan;35(1):35-43
pubmed: 25118001
Am J Med Genet A. 2009 May;149A(5):844-51
pubmed: 19334091
Clin Case Rep. 2017 Jan 23;5(2):164-169
pubmed: 28174644
Am J Med Genet A. 2013 Dec;161A(12):3078-86
pubmed: 24039125
Obstet Gynecol. 2014 Jul;124(1):83-90
pubmed: 24901266
Ultrasound Obstet Gynecol. 2002 May;19(5):510-3
pubmed: 11982988
Transfusion. 2017 Apr;57(4):876
pubmed: 28394424
Genet Med. 2011 Jul;13(7):680-5
pubmed: 21681106
Am J Obstet Gynecol. 2015 Mar;212(3):281-90
pubmed: 25305402
Pediatr Dev Pathol. 2019 Mar-Apr;22(2):166-170
pubmed: 30550718
Early Hum Dev. 2011 Aug;87(8):571-5
pubmed: 21592689
J Obstet Gynaecol Can. 2018 Aug;40(8):1077-1090
pubmed: 30103882
Prenat Diagn. 2018 Jan;38(2):140-147
pubmed: 29297200
Am J Med Genet A. 2015 Dec;167A(12):2966-74
pubmed: 26768185
Prenat Diagn. 2018 Apr;38(5):337-343
pubmed: 29500832
Obstet Gynecol Sci. 2015 Mar;58(2):90-7
pubmed: 25798421
Am J Med Genet A. 2013 Jan;161A(1):137-44
pubmed: 23239491
Genet Med. 2019 Jun;21(6):1339-1344
pubmed: 30410095

Auteurs

Anne H Mardy (AH)

Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco, California, USA.

Naseem Rangwala (N)

Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco, California, USA.

Yessenia Hernandez-Cruz (Y)

University of California, Berkeley, Berkeley, California, USA.

Kristen A Gosnell (KA)

University of California, Berkeley, Berkeley, California, USA.

Juan M Gonzalez (JM)

Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco, California, USA.
Fetal Treatment Center, University of California, San Francisco, San Francisco, California, USA.

Mary E Norton (ME)

Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco, California, USA.
Fetal Treatment Center, University of California, San Francisco, San Francisco, California, USA.

Teresa N Sparks (TN)

Division of Maternal Fetal Medicine, University of California, San Francisco, San Francisco, California, USA.
Fetal Treatment Center, University of California, San Francisco, San Francisco, California, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH